title: Autologous Conditioned Serum.
abstract: Autologous conditioned serum was developed in the mid 1990s as an expeditious, practical, and relatively inexpensive means of generating the interleukin-1 receptor antagonist, a naturally occurring inhibitor of the cytokine interleukin-1. The latter is thought to be an important mediator of inflammation, pain, and tissue destruction in musculoskeletal conditions. ACS has been widely and successfully used in the local treatment of human and equine osteoarthritis and radicular compression; it has also shown promise in treating tendinopathies, muscle injuries, and tunnel widening after reconstruction of the anterior cruciate ligament. Experience suggests that autologous conditioned serum is safe and effective.
authors: Rehabilitation Medicine Research Center, Mayo Clinic, 200, First Street Southwest, Rochester, MN 55905, USA. Electronic address: Evans.christopher@mayo.edu.
authors: Christopher H
authors: CH
authors: Evans
authors: Department of Rheumatology, Hopital Henri Mondor, UPEC Paris XII University, Bd De latter de Tassigny, Creteil 94010, France.
authors: Xavier
authors: X
authors: Chevalier
authors: Orthogen AG, Ernst-Schneider-Platz 1, Düsseldorf 40212, Germany.
authors: Peter
authors: P
authors: Wehling
mesh_terms: D000818:Animals; D001691:Biological Therapy; D006736:Horses; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use; D007375:Interleukin-1 / Q000627:therapeutic use; D009135:Muscular Diseases / Q000628:therapy*; D010146:Pain; D044967:Serum / Q000276:immunology*
chemical_list: D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1
keywords: Anterior cruciate ligament; Interleukin-1 receptor antagonist; Intra-articular therapy; Muscle injury; Osteoarthritis; Pain; Radicular compression; Tendinopathy